CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
Cancer Research and Treatment. 2020;52(3):661-670.   Published online 2020 January 10    DOI: https://doi.org/10.4143/crt.2019.718

Excel Download

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
Cancer Research and Treatment. 2020;52(3):661-670   Crossref logo
Link1 Link2 Link3

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
Human Pathology. 2019;87:11-17   Crossref logo
Link1 Link2

P2.01-049 A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung
Journal of Thoracic Oncology. 2017;12(1):S815-S816   Crossref logo
Link1 Link2

P2.09-14 Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer
Journal of Thoracic Oncology. 2019;14(10):S774   Crossref logo
Link1 Link2

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases. 2020;83(1):51   Crossref logo
Link1 Link2 Link3

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
Journal of Clinical Pathology. 2020;jclinpath-2020-206466   Crossref logo
Link1

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
Journal of Thoracic Oncology. 2017;12(11):1654-1663   Crossref logo
Link1 Link2

P2.09-06 Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
Journal of Thoracic Oncology. 2018;13(10):S761-S763   Crossref logo
Link1 Link2

CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
Thoracic Cancer. 2019;10(7):1612-1618   Crossref logo
Link1 Link2 Link3 Link4

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer
Gastric Cancer. 2018;22(1):69-76   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.